LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

31.25 0.16

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

30.88

Max

31.5

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-97M

Müük

361K

361K

Aktsiakasum

-1.04

Kasumimarginaal

-26,807.202

Töötajad

437

EBITDA

-6.9M

-94M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+148.72% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-41M

3.1B

Eelmine avamishind

31.09

Eelmine sulgemishind

31.25

Uudiste sentiment

By Acuity

54%

46%

315 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. mai 2025, 19:39 UTC

Suurimad hinnamuutused turgudel

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16. mai 2025, 23:18 UTC

Peamised uudised

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16. mai 2025, 22:30 UTC

Peamised uudised

U.S. Loses Last Triple-A Credit Rating -- Update

16. mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16. mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. mai 2025, 21:54 UTC

Peamised uudised

U.S. Loses Last Triple-A Credit Rating -- WSJ

16. mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16. mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16. mai 2025, 21:17 UTC

Peamised uudised

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16. mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16. mai 2025, 20:55 UTC

Omandamised, ülevõtmised, äriostud

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. mai 2025, 20:50 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

16. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. mai 2025, 20:37 UTC

Peamised uudised

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16. mai 2025, 20:33 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16. mai 2025, 20:30 UTC

Omandamised, ülevõtmised, äriostud

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16. mai 2025, 20:18 UTC

Peamised uudised

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16. mai 2025, 20:16 UTC

Peamised uudised

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16. mai 2025, 20:15 UTC

Tulu

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16. mai 2025, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Henry Schein: William K. Daniel Joins Board

16. mai 2025, 20:10 UTC

Omandamised, ülevõtmised, äriostud

Henry Schein: Strategic Investment by KKR Completed

16. mai 2025, 20:05 UTC

Omandamised, ülevõtmised, äriostud

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16. mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16. mai 2025, 18:51 UTC

Peamised uudised

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16. mai 2025, 18:41 UTC

Omandamised, ülevõtmised, äriostud

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. mai 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16. mai 2025, 18:35 UTC

Peamised uudised

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16. mai 2025, 18:32 UTC

Peamised uudised

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16. mai 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

148.72% tõus

12 kuu keskmine prognoos

Keskmine 77.7 USD  148.72%

Kõrge 100 USD

Madal 53 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

11

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

30.39 / 33.46Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

315 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.